BiotechTube
NeuroLutions

NeuroLutions

St. Louis, United States· Est.
neurolutions.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $14.5M

Overview

NeuroLutions is a commercial-stage medical device company pioneering a novel approach to stroke recovery. Its FDA-cleared IpsiHand system is a first-of-its-kind BCI therapy that enables patients to use signals from their uninjured brain hemisphere to drive movement in their impaired hand, offering hope beyond the traditional recovery plateau. The company has transitioned from R&D through regulatory milestones to a full market launch in 2024, focusing on home-based rehabilitation covered by major insurers. NeuroLutions represents a significant innovation in the neurorehabilitation space, targeting the large and underserved chronic stroke population.

Stroke RehabilitationNeurology

Technology Platform

Non-invasive electroencephalogram (EEG)-based brain-computer interface (BCI) that uses signals from the uninjured brain hemisphere to control a motorized exoskeleton for hand rehabilitation.

Funding History

3
Total raised:$14.5M
Grant$2M
Series A$10M
Seed$2.5M

Opportunities

The large and underserved chronic stroke population represents a multi-billion dollar market with limited effective treatment options.
The shift towards home-based rehabilitation and the company's first-mover advantage with an FDA-cleared BCI therapy create a significant growth opportunity.
Expansion of the core BCI platform to other neurological indications could further multiply the addressable market.

Risk Factors

Commercialization risk includes the challenge of driving widespread clinical adoption and navigating complex, case-by-case insurance reimbursement.
The company faces competitive risk from other emerging neurorehabilitation technologies and must continue to generate robust real-world evidence to support its value proposition.
As a private company, it remains dependent on investor funding to scale operations until achieving profitability.

Competitive Landscape

NeuroLutions competes in the neurorehabilitation and emerging therapeutic BCI space. Direct competitors include companies developing robotic exoskeletons, functional electrical stimulation devices, and other BCI systems for stroke recovery. Its primary competitive advantage is its FDA De Novo clearance as the first non-invasive BCI for stroke rehabilitation, a significant regulatory milestone. However, large medtech companies and well-funded startups are actively exploring adjacent technologies.

More companies in Neuroscience & CNS →More companies in United States →